De novo migraine with aura in the third trimester of pregnancy: a case report and literature review
De novo migraine with aura in the third trimester of pregnancy: a case report and literature review
Blog Article
Background: Among all headache disorders, migraine has the highest prevalence during gestation.The majority of migraineurs experience improvement during pregnancy, but a few may experience migraine for the first time.This poses a diagnostic challenge in the differential diagnosis between primary and life-threatening secondary headache disorders.
Because pregnancy itself is an independent risk factor for secondary headache disorders, it is mandatory to exclude these conditions in order to diagnose migraine.There is a large body of literature about pre-existing migraine course during pregnancy and its link with adverse pregnancy outcomes, but there are no HAND SOAP LAVENDER studies examining these aspects among women with new-onset migraine during pregnancy.Case report.
A 31-year-old female at 33 weeks of gestation (gravida 2, para 2) was referred to the neurologist eds disturbances, which were followed by pressing severe headache, rated as 8 out of 10 on a numeric rating scale and accompanied by dizziness.The headache lasted for one day, and dizziness continued to the following day.The patient was investigated for a secondary headache disorder, but laboratory and neuroimaging results were unremarkable.
A migraine with aura was diagnosed.The patient was advised to keep a consistent sleep schedule, maintain regular low physical activity, eat regularly and take magnesium supplementation.The patient was informed about a safe treatment approach in case of an acute attack.
At 40 weeks of gestation the patient delivered female newborn, weighing 3750g, with Apgar scores of 8 and 9 (due to a nuchal cord).The postpartum period was uneventful.During the subsequent 4 years, the patient did not experience any recurrent migraine attacks and had no pregnancies.
Conclusion.In order to diagnose a migraine during pregnancy, exclusion of secondary headache disorders is mandatory.Pregnant migraineur should be regularly monitored for adverse birth outcomes.
It TRIPHLAX-750 is essential to educate patients, provide information about the safe treatment of migraine attacks, and explain nonpharmacological prevention and supplementation benefits.